+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tropical & Vector-borne Infectious Diseases Market by Disease Type, Therapeutic Application, Diagnostic Method, End User - Global Forecast to 2030- Product Image
Tropical & Vector-borne Infectious Diseases Market by Disease Type, Therapeutic Application, Diagnostic Method, End User - Global Forecast to 2030- Product Image
Sale

Tropical & Vector-borne Infectious Diseases Market by Disease Type, Therapeutic Application, Diagnostic Method, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6082177
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Navigating the New Era of Tropical Disease Management

The global environment for managing tropical and vector-borne diseases has never been more complex or urgent. Accelerating climate shifts, expanding urbanization and evolving pathogen dynamics collide to create new challenges for healthcare systems and public health authorities. In this context, the need for a clear market perspective is paramount, empowering stakeholders to anticipate emerging threats, optimize resource allocation and drive innovative solutions.

This executive summary distills the most critical trends shaping disease prevalence, product development and market access. By synthesizing data across disease categories, therapeutic platforms and diagnostic technologies, it offers a holistic view that informs strategic planning. Through an exploration of regulatory shifts, tariff impacts and competitive strategies, decision-makers will gain a nuanced understanding of both obstacles and opportunities.

Our goal is to equip industry leaders, policy-makers and investors with a concise yet comprehensive roadmap. By focusing on transformative shifts and actionable recommendations, this overview provides the foundation for informed decisions today and presents a forward-looking lens on tomorrow’s innovations in combating Chagas disease, dengue, leishmaniasis, malaria, West Nile virus and Zika virus.

Transformative Shifts Redefining Disease Control and Innovation

Unprecedented environmental changes are reshaping vector habitats and disease transmission corridors. Rising temperatures extend the breeding seasons for Aedes and Anopheles mosquitoes, while extreme weather events disrupt traditional control measures and strain public health infrastructures. At the same time, rapid advances in genomic sequencing and point-of-care diagnostics are transforming how outbreaks are detected and contained, offering faster, more precise identification of pathogens at the community level.

Concurrently, policy landscapes are shifting. Increased funding for pandemic preparedness and antimicrobial resistance has bolstered research pipelines, but evolving trade policies and intellectual property debates introduce new complexities for global distribution. Clinical development timelines have compressed as public and private sectors collaborate on adaptive clinical trial models and real-world evidence generation. Moreover, vector resistance to insecticides has intensified, driving investment in novel biocontrol strategies, gene editing and next-generation repellents.

Taken together, these trends signal a market in flux, where agility and innovation will determine winners. Organizations that can integrate cross-sector partnerships, harness emerging technologies and navigate dynamic regulatory frameworks will be best positioned to lead the fight against tropical and vector-borne diseases.

Tariff Shocks Reshaping Cost Structures and Supply Chains in 2025

The implementation of new United States tariffs in 2025 has introduced a significant layer of complexity to supply chains for vaccines, diagnostics reagents and vector control equipment. Costs for raw materials sourced from key exporting nations have risen, prompting manufacturers to reassess procurement strategies and pass through incremental expenses to downstream buyers. Diagnostics centers and hospitals face tighter budgets as essential consumables become more expensive, while research institutes encounter constraints on importing high-precision molecular diagnostics instruments.

In response, many stakeholders have diversified supplier networks, seeking regional manufacturing hubs and alternative sourcing agreements to mitigate exposure. Some vaccine developers have accelerated local fill-finish capabilities to circumvent tariff barriers, although these shifts often require substantial upfront capital and time. Meanwhile, collaborations between public agencies and industry players have emerged to lobby for temporary exemptions on life-saving biologics and diagnostics, acknowledging their critical role in epidemic control.

These tariff measures have not only affected cost structures but also accelerated conversations around on-shoring and near-shoring of production. As organizations adapt to this new reality, resilience and supply chain transparency have become strategic imperatives. Companies that proactively realign logistics, invest in local manufacturing and engage in policy dialogue will be better equipped to absorb the financial impact and maintain uninterrupted access to vital medical products.

Nuanced Perspectives from Market Segmentation

Our analysis of disease type segmentation reveals distinct market dynamics across the spectrum of vector-borne pathogens. Chagas disease remains a critical concern in Latin American regions, while dengue’s urban outbreaks demand scalable vaccine and therapeutic solutions. Leishmaniasis and malaria continue to drive demand for both rapid diagnostics and long-standing antimalarial regimens, and the sporadic emergence of West Nile virus and Zika virus sparks targeted research into next-generation immunoprophylaxis.

When examining therapeutic applications, immunoglobulin therapies, both monoclonal and polyclonal, are gaining traction for immune modulation, even as established antibiotic, antimalarial and antiviral treatments retain their prominence. Vaccine development spans from traditional live attenuated platforms to cutting-edge mRNA constructs and recombinant formulations, each offering unique profiles in safety, efficacy and manufacturing complexity.

Diagnostic methods further segment the market by technological sophistication. Traditional microscopy remains a cornerstone in resource-limited settings, whereas molecular diagnostics, including loop-mediated isothermal amplification and PCR, deliver unparalleled sensitivity. Rapid diagnostic tests such as those for chikungunya, dengue and malaria facilitate on-site triage, and serological assays complement molecular approaches by mapping immune responses at both individual and population levels.

End-user segmentation underscores differing procurement cycles and usage patterns. Diagnostic centers prioritize speed and ease of use, hospitals and clinics balance cost with comprehensive care pathways, and research institutes demand high-throughput, customizable platforms. Understanding these varied needs allows suppliers to tailor solutions that optimize adoption and outcomes across the healthcare ecosystem.

Regional Dynamics Driving Market Opportunities and Challenges

In the Americas, a blend of public health investment and private sector innovation drives robust pipelines for vaccines and diagnostics. Collaboration between governmental agencies and biotechnology firms has accelerated vaccine candidate approvals, while regional manufacturing capacity continues to expand. However, disparities in healthcare access across urban and rural areas persist, challenging equitable distribution of prevention and treatment tools.

Europe, Middle East and Africa present a mosaic of regulatory frameworks and healthcare infrastructures. High regulatory standards in Europe coexist with pressing vectorborne outbreaks in parts of the Middle East and North Africa, where surveillance programs and emergency response mechanisms are still maturing. Sub-Saharan Africa’s burden of malaria underscores the need for enhanced funding and local production to meet the dual goals of affordability and sustainable supply.

Asia-Pacific exemplifies rapid commercialization and technological adoption, with several countries emerging as hubs for mRNA vaccine manufacturing and molecular diagnostic innovation. National strategies in countries such as India and China emphasize self-reliance, fostering domestic R&D and export-oriented growth. Yet, supply chain vulnerabilities exposed during recent outbreaks highlight the importance of diversified sourcing and resilient distribution networks throughout the region.

Navigating the Competitive Landscape with Key Industry Players

Leading companies are differentiating through integrated portfolios that span diagnostics, therapeutics and preventive measures. Some global biopharma firms are advancing hybrid vaccine platforms that combine mRNA technologies with adjuvant systems to enhance immunogenicity against dengue and Zika. Diagnostic developers are partnering with digital health providers to embed real-time data analytics and remote connectivity into rapid test solutions, enabling proactive surveillance and response.

Strategic collaborations are shaping the competitive landscape. Research alliances between academic institutions and industry players have accelerated translational studies into novel insect-targeted biologics and vector-resistance breakers. Meanwhile, mergers and acquisitions are consolidating niche diagnostic specialists and expanding distribution footprints in high-demand geographies. Companies that leverage these synergies can reduce time-to-market, optimize R&D spend and strengthen negotiating power with public procurement agencies.

Innovation in manufacturing is also a key differentiator. Organizations that have invested in modular, flexible production lines can switch seamlessly between vaccine and diagnostic reagent outputs, responding swiftly to shifting epidemiological priorities. This agility, coupled with robust quality management systems, positions them to meet stringent regulatory expectations and fulfill large-scale contracts during epidemic surges.

Strategic Actions for Leadership and Growth

To capitalize on emerging opportunities, industry leaders should deepen collaborative ties with public health authorities, ensuring that R&D agendas align with evolving disease burdens. Strengthening alliances with regional manufacturing partners will mitigate tariff and logistical risks while fostering local capacity building. Simultaneously, investing in end-to-end supply chain transparency through digital platforms will enhance resilience and enable rapid response to demand fluctuations.

Incorporating adaptive clinical trial designs will accelerate time to approval for novel therapeutics and vaccines, particularly for diseases with sporadic outbreak patterns. Leveraging real-world evidence from pilot implementations of rapid diagnostics can inform product refinements and support reimbursement discussions. Furthermore, companies should explore co-development models for diagnostics and therapeutics, creating bundled offerings that deliver comprehensive care protocols to end users.

Finally, prioritizing market access strategies in underserved regions will not only address critical public health needs but also unlock significant growth potential. Tailoring pricing models to local economic contexts and partnering with non-governmental organizations for distribution can ensure sustainable adoption and long-term impact.

Rigorous Framework Behind Our Insights

This research synthesizes both primary and secondary data to deliver a robust market portrait. Key insights derive from in-depth interviews with industry executives, clinical experts and public health officials, ensuring firsthand perspectives on innovation drivers and market barriers. These discussions were complemented by exhaustive reviews of regulatory filings, patent databases and academic literature to capture the latest scientific and technological developments.

Quantitative data were triangulated across multiple reputable sources, including procurement databases, conference proceedings and company disclosures, to validate market trends and durable shifts. The methodology also leverages scenario analysis to assess the potential impact of emerging variables such as tariff changes and climate acceleration on supply chains and investment flows.

Rigorous quality checks, including cross-validation exercises and peer reviews, underpin the credibility of our findings. This comprehensive approach ensures that conclusions and recommendations are not only evidence-based but also adaptable to the fluid nature of tropical and vector-borne disease markets.

Synthesizing Insights for Future Readiness

The convergence of environmental, regulatory and technological forces is transforming the tropical and vector-borne disease landscape. As tariffs reshape cost equations and segmentation insights reveal tailored growth avenues, the imperative for strategic agility becomes clear. Companies that harness advanced diagnostics, pivot toward flexible manufacturing and align with public health priorities will lead the next wave of innovation.

Looking ahead, the market will increasingly favor integrated solutions that span prevention, detection and treatment. Digital health integration, modular production platforms and public-private partnerships will be critical in addressing unpredictable outbreak patterns and supply chain vulnerabilities. By staying attuned to regional dynamics and emerging therapeutic breakthroughs, stakeholders can turn complexity into opportunity and drive sustainable impact against some of the world’s most persistent infectious threats.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Disease Type
    • Chagas Disease
    • Dengue
    • Leishmaniasis
    • Malaria
    • West Nile Virus
    • Zika Virus
  • Therapeutic Application
    • Immunoglobulins
      • Monoclonal
      • Polyclonal
    • Therapeutics
      • Antibiotics
      • Antimalarials
      • Antivirals
    • Vaccines
      • Live Attenuated
      • mRNA
      • Recombinant
  • Diagnostic Method
    • Microscopy
    • Molecular Diagnostics
      • LAMP
      • PCR
    • Rapid Diagnostic Tests
      • Chikungunya RDT
      • Dengue RDT
      • Malaria RDT
    • Serological Tests
  • End User
    • Diagnostic Centers
    • Hospitals & Clinics
    • Research Institutes
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
  • Bavarian Nordic A/S
  • Moderna, Inc.
  • Bharat Biotech International Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tropical & Vector-borne Infectious Diseases Market, by Disease Type
8.1. Introduction
8.2. Chagas Disease
8.3. Dengue
8.4. Leishmaniasis
8.5. Malaria
8.6. West Nile Virus
8.7. Zika Virus
9. Tropical & Vector-borne Infectious Diseases Market, by Therapeutic Application
9.1. Introduction
9.2. Immunoglobulins
9.2.1. Monoclonal
9.2.2. Polyclonal
9.3. Therapeutics
9.3.1. Antibiotics
9.3.2. Antimalarials
9.3.3. Antivirals
9.4. Vaccines
9.4.1. Live Attenuated
9.4.2. mRNA
9.4.3. Recombinant
10. Tropical & Vector-borne Infectious Diseases Market, by Diagnostic Method
10.1. Introduction
10.2. Microscopy
10.3. Molecular Diagnostics
10.3.1. LAMP
10.3.2. PCR
10.4. Rapid Diagnostic Tests
10.4.1. Chikungunya RDT
10.4.2. Dengue RDT
10.4.3. Malaria RDT
10.5. Serological Tests
11. Tropical & Vector-borne Infectious Diseases Market, by End User
11.1. Introduction
11.2. Diagnostic Centers
11.3. Hospitals & Clinics
11.4. Research Institutes
12. Americas Tropical & Vector-borne Infectious Diseases Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Tropical & Vector-borne Infectious Diseases Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Tropical & Vector-borne Infectious Diseases Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. GlaxoSmithKline plc
15.3.2. Sanofi S.A.
15.3.3. Pfizer Inc.
15.3.4. Merck & Co., Inc.
15.3.5. Johnson & Johnson
15.3.6. Takeda Pharmaceutical Company Limited
15.3.7. Valneva SE
15.3.8. Bavarian Nordic A/S
15.3.9. Moderna, Inc.
15.3.10. Bharat Biotech International Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET MULTI-CURRENCY
FIGURE 2. TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET MULTI-LANGUAGE
FIGURE 3. TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CHAGAS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DENGUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MALARIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY WEST NILE VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ZIKA VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY POLYCLONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIMALARIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY LAMP, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY CHIKUNGUNYA RDT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DENGUE RDT, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MALARIA RDT, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 67. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 68. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 69. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 70. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 71. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 72. CANADA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 78. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 79. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 80. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 81. MEXICO TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. GERMANY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 120. GERMANY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. GERMANY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 122. GERMANY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 123. GERMANY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 124. GERMANY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 125. GERMANY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 126. GERMANY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 127. GERMANY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. FRANCE TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 129. FRANCE TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. FRANCE TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 131. FRANCE TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 132. FRANCE TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 133. FRANCE TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 134. FRANCE TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 135. FRANCE TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 136. FRANCE TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. ITALY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 147. ITALY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. ITALY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 149. ITALY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 150. ITALY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 151. ITALY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 152. ITALY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 153. ITALY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 154. ITALY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SPAIN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 156. SPAIN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. SPAIN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 158. SPAIN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 159. SPAIN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 160. SPAIN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 161. SPAIN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 162. SPAIN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 163. SPAIN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. DENMARK TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 192. DENMARK TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. DENMARK TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 194. DENMARK TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 195. DENMARK TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 196. DENMARK TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 197. DENMARK TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 198. DENMARK TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 199. DENMARK TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. QATAR TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 210. QATAR TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. QATAR TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 212. QATAR TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 213. QATAR TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 214. QATAR TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 215. QATAR TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 216. QATAR TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 217. QATAR TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. FINLAND TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 219. FINLAND TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. FINLAND TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 221. FINLAND TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 222. FINLAND TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 223. FINLAND TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 224. FINLAND TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 225. FINLAND TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 226. FINLAND TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. EGYPT TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 246. EGYPT TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. EGYPT TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 248. EGYPT TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 249. EGYPT TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 250. EGYPT TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 251. EGYPT TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 252. EGYPT TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 253. EGYPT TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. TURKEY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 255. TURKEY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 256. TURKEY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 257. TURKEY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 258. TURKEY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 259. TURKEY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 260. TURKEY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 261. TURKEY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
TABLE 262. TURKEY TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY DIAGNOSTIC METHOD, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL TROPICAL & VECTOR-BORNE INFECTIOUS DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Tropical & Vector-borne Infectious Diseases market report include:
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
  • Bavarian Nordic A/S
  • Moderna, Inc.
  • Bharat Biotech International Limited

Related Topics

Related Reports

Infectious Disease Diagnostic Market by Product, Sample Type, Technology, Testing Type, Disease Type, End-User - Global Forecast to 2030 - Product Image

Infectious Disease Diagnostic Market by Product, Sample Type, Technology, Testing Type, Disease Type, End-User - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets 2025-2029: Strategies, Trends, and Forecasts by Application, Place and Country with Market Analysis & Executive Guides - Product Image

Clinical Laboratory Molecular Diagnostics for Infectious Disease Markets 2025-2029: Strategies, Trends, and Forecasts by Application, Place and Country with Market Analysis & Executive Guides

  • Report
  • 354 Pages
  • Global
From
Neglected Tropical Disease Treatment - Global Strategic Business Report - Product Image

Neglected Tropical Disease Treatment - Global Strategic Business Report

  • Report
  • 294 Pages
  • Global
From
Arthropod-Borne Viral Infection Testing Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Arthropod-Borne Viral Infection Testing Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Zika Virus Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Zika Virus Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.